相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
20.0%
终止
3
60.0%
撤回
1
20.0%
暂无批准数据
- Xoma Royalty has agreed to acquire Generation Bio, a struggling gene therapy developer, for approximately $4.29 per share in its latest "zombie biotech" acquisition. - Generation Bio raised $200 million in its 2020 IPO to develop lipid nanoparticle-based gene therapy technology but faced setbacks including disappointing preclinical results and workforce reductions. - The acquisition includes contingent value rights for shareholders, potentially providing additional payments from cash holdings, lease savings, Moderna partnership milestones, and proceeds from delivery technology sales. - Generation Bio recently slashed 90% of its workforce and began strategic review after touting RNA delivery technology for T cells, fitting Xoma's pattern of acquiring distressed biotech companies.
- XOMA Royalty Corporation reported robust financial performance in Q3 2025, receiving $43.9 million in royalties and milestones from partners in the first nine months of 2025, including $14.3 million in Q3 royalties. - The company completed strategic acquisitions of Turnstone Biologics and HilleVax while announcing planned acquisitions of LAVA Therapeutics and Mural Oncology to expand its royalty portfolio. - Key pipeline developments include Zevra Therapeutics submitting a Marketing Authorization Application to the EMA for arimoclomol in Niemann-Pick Type C disease and Rezolute Bio expecting Phase 3 ersodetug trial results in December 2025. - XOMA Royalty achieved net income of $14.1 million in Q3 2025 compared to a net loss of $17.2 million in the same period of 2024, demonstrating improved operational performance.
- XOMA Royalty's subsidiary XRA 5 Corp. will acquire clinical-stage immuno-oncology company Mural Oncology for $2.035 per share base price, potentially reaching $36.2 million total value. - The acquisition represents a 13.1% premium over Mural's recent share price and a 97.6% premium over pre-strategic review value, maximizing shareholder returns. - This deal continues XOMA's aggressive 2025 acquisition strategy, following recent mergers with HilleVax and Turnstone Biologics to expand its late-stage biotech portfolio.
- Xoma Royalty Corp. agreed to acquire Mural Oncology for $2.035-2.240 per share, valuing the deal at $35.2-38.8 million depending on closing cash balance. - The acquisition follows Mural's discontinuation of lead IL-2 therapy nemvaleukin alfa after failed Artistry-6 and 7 trials, leading to 90% workforce reduction in April. - Xoma will wind down Mural's operations as part of a growing trend where investment firms acquire struggling biotechs trading below cash value for liquidation. - The deal represents Xoma's fourth oncology acquisition this year, following purchases of Turnstone Biologics, Lava Therapeutics, and HilleVax.
- Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts. - Companies are shifting from broad R&D portfolios to focused pipeline optimization, with firms like Shattuck Labs and Relay Therapeutics narrowing their therapeutic focus to core projects with highest potential returns. - The layoffs reflect strategic responses to investor pressure for capital discipline, post-pandemic demand shifts, and the need to extend cash reserves while maintaining progress on lead clinical programs. - Industry consolidation and increased outsourcing to contract research organizations are driving operational realignment, as companies seek to reduce overhead costs and access specialized expertise without maintaining high-cost facilities.
- Turnstone Biologics has halted the development of TIDAL-01, their selected tumor infiltrating lymphocyte (TIL) therapy, citing capital-intensive manufacturing requirements and current market conditions. - The phase 1 STARLING trial showed early efficacy with 25% objective response rate in MSS colorectal cancer patients, including one durable complete response. - The discontinuation affects multiple clinical trials, including the STARLING study and Moffitt Cancer Center-sponsored melanoma trial, marking a significant setback in TIL therapy development.
- Turnstone Biologics announces immediate discontinuation of all clinical studies for its Selected TIL therapy TIDAL-01, citing capital-intensive manufacturing requirements and challenging financial market conditions. - The company has initiated a strategic review process to maximize shareholder value, exploring options including potential merger, acquisition, or asset sale while implementing workforce reductions. - Management is retaining essential employees and engaging financial advisors to support the strategic alternatives evaluation process while implementing cost-containment measures.
• Turnstone Biologics is prioritizing its clinical program, TIDAL-01, a Selected TIL therapy, and streamlining operations to extend its cash runway into the second quarter of 2026. • The company is reducing its workforce by approximately 60% as part of a strategic realignment to focus on clinical development and manufacturing efforts. • Initial Phase 1 data from the STARLING trial supports the biological hypothesis for TIL selection, showcasing a complete response in a heavily pre-treated MSS-CRC patient. • Leadership transitions include Ines Verdon assuming leadership of clinical activities and Michael Fitch overseeing manufacturing, with other changes in finance and operations.
• The FDA approved Roche's Itovebi, inavolisib, for HR-positive, HER2-negative breast cancer with PIK3CA mutation, to be used with Pfizer’s Ibrance and endocrine therapy. • Turnstone Biologics is restructuring, laying off 60% of its workforce to focus on a Phase 1 cancer cell therapy program for solid tumors, with updates expected next year. • Pfizer's Talzenna combined with Xtandi showed prolonged survival in advanced prostate cancer patients, regardless of genetic alterations, seeking expanded use. • Gritstone bio filed for bankruptcy after disappointing vaccine study results; Denali Therapeutics' multiple sclerosis drug, oditrasertib, failed in Phase 2 trial.
